FDA Clearance of Amplia’s IND for Pancreatic Cancer Trial in US
Amplia Therapeutics Limited, is pleased to announce that the US FDA have cleared Amplia’s IND application for a trial of Amplia’s best-in-class focal adhesion kinase inhibitor narmafotinib in pancreatic cancer.
FDA Clearance of Amplia’s IND for Pancreatic Cancer Trial in US Read More »
